JP6816106B2 - 6−ピリジル−1,3,5−トリアジン−2,4−ジオール及び6−ピリジル−1,3,5−トリアジン−2,4−ジアミンを調製する方法 - Google Patents

6−ピリジル−1,3,5−トリアジン−2,4−ジオール及び6−ピリジル−1,3,5−トリアジン−2,4−ジアミンを調製する方法 Download PDF

Info

Publication number
JP6816106B2
JP6816106B2 JP2018505739A JP2018505739A JP6816106B2 JP 6816106 B2 JP6816106 B2 JP 6816106B2 JP 2018505739 A JP2018505739 A JP 2018505739A JP 2018505739 A JP2018505739 A JP 2018505739A JP 6816106 B2 JP6816106 B2 JP 6816106B2
Authority
JP
Japan
Prior art keywords
compound
formula
acid
certain embodiments
reacted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018505739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528182A (ja
JP2018528182A5 (enExample
Inventor
ズハング シジエ
ズハング シジエ
Original Assignee
アジオス ファーマシューティカルズ, インコーポレイテッド
アジオス ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジオス ファーマシューティカルズ, インコーポレイテッド, アジオス ファーマシューティカルズ, インコーポレイテッド filed Critical アジオス ファーマシューティカルズ, インコーポレイテッド
Publication of JP2018528182A publication Critical patent/JP2018528182A/ja
Publication of JP2018528182A5 publication Critical patent/JP2018528182A5/ja
Application granted granted Critical
Publication of JP6816106B2 publication Critical patent/JP6816106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2018505739A 2015-08-05 2016-08-04 6−ピリジル−1,3,5−トリアジン−2,4−ジオール及び6−ピリジル−1,3,5−トリアジン−2,4−ジアミンを調製する方法 Active JP6816106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201546P 2015-08-05 2015-08-05
US62/201,546 2015-08-05
PCT/US2016/045553 WO2017024134A1 (en) 2015-08-05 2016-08-04 Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020213670A Division JP2021063097A (ja) 2015-08-05 2020-12-23 6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジオール及び6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジアミンを調製する方法

Publications (3)

Publication Number Publication Date
JP2018528182A JP2018528182A (ja) 2018-09-27
JP2018528182A5 JP2018528182A5 (enExample) 2019-09-19
JP6816106B2 true JP6816106B2 (ja) 2021-01-20

Family

ID=56684781

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018505739A Active JP6816106B2 (ja) 2015-08-05 2016-08-04 6−ピリジル−1,3,5−トリアジン−2,4−ジオール及び6−ピリジル−1,3,5−トリアジン−2,4−ジアミンを調製する方法
JP2020213670A Pending JP2021063097A (ja) 2015-08-05 2020-12-23 6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジオール及び6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジアミンを調製する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020213670A Pending JP2021063097A (ja) 2015-08-05 2020-12-23 6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジオール及び6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジアミンを調製する方法

Country Status (8)

Country Link
US (1) US9751863B2 (enExample)
EP (1) EP3331866B1 (enExample)
JP (2) JP6816106B2 (enExample)
CN (1) CN108349933A (enExample)
AU (2) AU2016303614A1 (enExample)
CA (1) CA2993615A1 (enExample)
MX (1) MX365590B (enExample)
WO (1) WO2017024134A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021063097A (ja) * 2015-08-05 2021-04-22 アジオス ファーマシューティカルズ, インコーポレイテッド 6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジオール及び6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジアミンを調製する方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ, インコーポレイテッド 悪性腫瘍の治療のための併用療法
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
KR102498693B1 (ko) 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220401450A1 (en) 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
CN111592524B (zh) * 2020-05-20 2023-11-17 温州市天聚万迅信息科技有限公司 恩西德尼的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS5170779A (ja) * 1974-12-17 1976-06-18 Nippon Shinyaku Co Ltd Shinkinaguanamidoruino seiho
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
DE59106971D1 (de) 1990-07-12 1996-01-11 Ciba Geigy Ag Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien.
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンa3拮抗剤
WO2000075129A1 (en) 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
WO2008131547A1 (en) 2007-04-30 2008-11-06 Prometic Biosciences Inc. 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives'
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
CA2764785C (en) 2009-06-08 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
MX375030B (es) 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
CN105916507A (zh) 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN108349933A (zh) * 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021063097A (ja) * 2015-08-05 2021-04-22 アジオス ファーマシューティカルズ, インコーポレイテッド 6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジオール及び6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジアミンを調製する方法

Also Published As

Publication number Publication date
US9751863B2 (en) 2017-09-05
JP2018528182A (ja) 2018-09-27
EP3331866A1 (en) 2018-06-13
MX2018001424A (es) 2018-08-01
US20170037031A1 (en) 2017-02-09
CA2993615A1 (en) 2017-02-09
MX365590B (es) 2019-06-07
EP3331866B1 (en) 2023-07-26
CN108349933A (zh) 2018-07-31
AU2016303614A1 (en) 2018-02-15
AU2021200494A1 (en) 2021-03-11
JP2021063097A (ja) 2021-04-22
WO2017024134A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
JP2021063097A (ja) 6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジオール及び6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジアミンを調製する方法
AU2013296627C9 (en) Deuterated ibrutinib
WO2025092986A1 (en) Polycyclic compound, preparation methods and medicinal uses thereof
JP7278273B2 (ja) アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン
US20220119370A1 (en) Brd4-jak2 inhibitors
US20110082147A1 (en) Substituted imidazotriazines
MX2011002278A (es) Derivados de triazolo-piridazina sustituidos.
WO2011116066A1 (en) Derivatives of dimethylcurcumin
AU2014235462A1 (en) Deuterated palbociclib
EP1446382B1 (en) Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors
JP2024543477A (ja) ユビキチン特異的プロテアーゼ1(usp1)の小分子阻害剤及びその使用
JP2023522863A (ja) Egfr阻害剤としての三環式化合物
JP7691974B2 (ja) アセチル補酵素aシンテターゼ短鎖2(acss2)の小分子阻害剤
JP7273030B6 (ja) シクロオレフィン置換複素芳香族化合物およびそれらの使用
CN116514728A (zh) 一种喹唑啉衍生物及其用途
CA3253274A1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECIPIENT
TWI874960B (zh) 聯芳組成物和調控激酶級聯之方法
CN120590368A (zh) 一种pcsk9抑制剂及其应用
CN117229292B (zh) Ret抑制剂的制备及其应用
WO2009023495A2 (en) Bisubstrate inhibitors of adenylosuccinate synthetase
AU2024323272A1 (en) Jak inhibitor compound and use thereof
WO2025106691A9 (en) Alpha 4 beta 7 integrin modulators and uses thereof
CN105878243B (zh) 吡非尼酮衍生物在制药中的应用
TW202610644A (zh) Cbl-b抑制劑的前藥化合物
TW202128647A (zh) 新的醯胺類化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201223

R150 Certificate of patent or registration of utility model

Ref document number: 6816106

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250